NCT06138132
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Recruiting · Phase 1 · Stanford University · registry updated 2026-02-27
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
Inclusion
- Patient is ≥ 18 years old, and ≤65 years of age, at time of screening visit.
- Diagnosis of MS according to the 2017 McDonald Criteria.
- Progressive MS by 2014 Lublin MS phenotypic criteria.
- Presence of varicella-zoster virus (VZV) antibodies, or completion of at least one dose of the varicella zoster glycoprotein E (gE) Shingrix vaccine at least four weeks prior to treatment.
- Presence of anti EBV antibodies.
- Organ and Marrow Function
Exclusion
- History of neuromyelitis optica spectrum disorder (NMOSD) or MOG antibody associated disease (MOGAD).
- Prior treatment with any investigational agent within 3 months, or 5 half-lives, whichever is longer. Agents authorized by the FDA for prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not considered investigational.
- Initiation of any DMT between the completion of apheresis and start of lymphodepletion (LD) chemotherapy. The use of methylprednisolone for bridging therapy between apheresis and start of LD chemotherapy will be allowed.
- History of CNS or spinal cord tumor, metabolic or infectious cause of myelopathy, genetically inherited progressive CNS disorder, sarcoidosis or non-MS progressive neurologic condition affecting ability to perform study assessments.
- History of cytopenia consistent with the diagnosis of myelodysplastic syndrome (MDS).
- History of sickle cell anemia or other hemoglobinopathy.